重组人干扰素α-2a栓与保妇康栓联合治疗慢性宫颈炎合并人乳头状瘤病毒感染的疗效分析
2016-08-30林学科张
林学科张 敏
重组人干扰素α-2a栓与保妇康栓联合治疗慢性宫颈炎合并人乳头状瘤病毒感染的疗效分析
林学科1张 敏2
目的 探究重组人干扰素α-2a栓与保妇康栓联合治疗慢性宫颈炎合并人乳头状瘤病毒感染的临床疗效。方法 根据药物治疗方案不同将门诊收治的75例慢性宫颈炎合并HPV感染患者分为联合组(40例)和对照组(35例),分别给予重组人干扰素α-2a栓联合保妇康栓和单独给予保妇康栓治疗,比较两组临床治疗效果。结果 联合组治疗后患者平均异常分泌物持续时间和创面愈合时间均短于对照组,治疗总有效率(97.5%)和3个月后HPV转阴率(45.0%)均高于对照组(82.9%、22.9%),比较差异有统计学意义(P<0.05)。结论 重组人干扰素α-2a栓联合保妇康栓治疗慢性宫颈炎合并HPV感染疗效满意,且安全性高。
慢性宫颈炎;HPV感染;保妇康栓;重组人干扰素α-2a栓
doi:10.3969/j.issn.1674-9316.2016.13.086
【Abstract】
Objective Analysis of recombinant human interferon alpha-2a suppository and Baofukang suppository in the treatment of chronic cervicitis combined with HPV infection. Methods According to the different drugs for treatment of the clinic from 75 cases of chronic cervicitis with HPV infection were divided into combined group(40 cases)and control group(35 cases)were given recombinant human interferon alfa-2asuppository combined with Baofukang suppository and given alone Baofukang suppository in the treatment,then compared two groups of clinical treatment effect. Results The combined treatment group patients after average abnormal discharge duration and the time of wound healing were shorter than that of the control group. The total treatment efficiency(97.5%)and 3 months after HPV negative rate(45.0%)were higher than control group (82.9%,22.9%),the difference had statistical significance(P<0.05). Conclusion Recombinant human interferon alpha -2a suppository combined with Baofukang suppository in the treatment of chronic cervicitis complicated with HPV infection have curative effect and high safety.
1 资料与方法
1.1一般资料
我院2015年3~12月门诊收治慢性宫颈炎合并HPV感染患者75例,均经妇科常规检查并确诊,对于合并阴道炎症、已出现癌变、有既往胎盘异常病史及药物过敏史患者予以排除。根据药物治疗方案不同,将上述患者分为联合组和对照组,联合组共40例,年龄为35~55岁,平均年龄为(42.8±5.4)岁,平均病程为(15.5±3.6)个月,病情程度:轻度12例,中度18例,重度10例;对照组共35例,年龄为36~55岁,平均年龄为(42.9±5.5)岁,平均病程为(15.6±3.7)个月,病情程度:轻度10例,中度17例,重度8例。两组患者基线资料(包括年龄、病程和病情)对比差异无统计学意义(P>0.05),具有可比性。
1.2方法
所有患者均接受药物保守治疗,先行……
